Discover
SLNO
Soleno Therapeutics, Inc.
53.01
2 x 38.15
2 x 67.82
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 14.49% | |
| 1y | -29.33% |
52.98
day range
53.01
29.43
52 week range
72.99
| Open | 52.99 | Prev Close | 53.01 | Low | 52.98 | High | 53.01 | Mkt Cap | 2.76B |
| Vol | 4.97M | Avg Vol | 1.75M | EPS | 1.77 | P/E | 27.09 | Forward P/E | 13.12 |
| Beta | -2.22 | Short Ratio | 1.01 | Inst. Own | 111.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 45.78 | 200-d Avg | 51.16 | 1yr Est | 53.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | 0.91 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | 0.73 | 0.59 | -0.14 | -19.18% |
| 2026-02-25 | 2025-12 | 0.64 | 0.8 | 0.16 | 25.00% |
| 2025-11-04 | 2025-09 | 0.06 | 0.47 | 0.41 | 717.39% |
| 2025-08-06 | 2025-06 | -0.53 | -0.09 | 0.44 | 83.02% |
| 2025-05-07 | 2025-03 | -1.14 | -0.95 | 0.19 | 16.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-17 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2026-04-08 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-04-07 | TD Cowen | Downgrade | Buy | Hold |
| 2026-04-07 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| 2026-04-06 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| 2026-03-18 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-20 | ANISH BHATNAGAR | Chief Executive Officer | 583.66K | Stock Award(Grant) |
| 2026-03-01 | FULK JENNIFER | Chief Financial Officer | 39.20K | Conversion of Exercise of derivative security |
| 2026-01-20 | HIRANO PATRICIA C | Officer | 22.70K | Stock Award(Grant) |
| 2026-03-26 | HUANG MICHAEL F | Officer | 39.82K | Sale |
| 2026-01-20 | JOSHI MANHER | Officer | 20.17K | Stock Award(Grant) |
| 2026-01-20 | MACKANESS JAMES H | Chief Financial Officer | 131.76K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | HHG PLC | 7.10M | 0.00 | 13.62% |
| 2026-03-30 | FMR Inc | 5.79M | 0.00 | 11.11% |
| 2026-03-30 | Wellington Management Company LLP | 4.43M | 0.00 | 8.49% |
| 2026-03-30 | BlackRock Inc | 3.74M | 0.00 | 7.18% |
| 2025-12-30 | Vanguard Group Inc | 3.06M | 0.00 | 5.87% |
| 2026-03-30 | State Street Corp | 2.68M | 0.00 | 5.14% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Vanguard Health Care Inv | 3.01M | 0.00 | 5.78% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 1.56M | 0.00 | 3.00% |
| 2026-03-30 | Janus Henderson Global Life Sciences | 987.38K | 0.00 | 1.89% |
| 2026-03-30 | Janus Henderson Global Life Sciences D | 987.38K | 0.00 | 1.89% |
| 2026-03-30 | Janus Global Life Science AUSD | 910.95K | 0.00 | 1.75% |
| 2026-04-29 | International Biotechnology Ord | 648.53K | 0.00 | 1.24% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2022-08-26 |
| 1 : 5 | 2017-10-06 |